US Stock MarketDetailed Quotes

DCTH Delcath Systems

Watchlist
  • 16.280
  • 0.0000.00%
Close Feb 14 16:00 ET
  • 16.428
  • +0.148+0.91%
Post 20:01 ET
589.34MMarket Cap-13.91P/E (TTM)

About Delcath Systems Company

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded in August 1988 and is headquartered in Queensbury, NY.

Company Profile

SymbolDCTH
Company NameDelcath Systems
Issue Price10.00
Founded1988
CEOMr. Gerard J. Michel
MarketNASDAQ
Employees76
Fiscal Year Ends12-31
Address566 Queensbury Avenue
CityQueensbury
ProvinceNew York
CountryUnited States of America
Zip Code12804
Phone1-212-489-2100

Company Executives

  • Name
  • Position
  • Salary
  • Gerard J. Michel
  • Interim Principal Accounting Officer, Director, President and Chief Executive Officer
  • 2.52M
  • Dr. Martha S. Rook, PhD
  • Chief Operating Officer
  • --
  • David L. Hoffman
  • General Counsel, Chief Compliance Officer and Corporate Secretary
  • --
  • Kevin Muir
  • General Manager, Interventional Oncology
  • 1.02M
  • Sandra Pennell
  • Senior Vice President, Finance
  • --
  • Dr. Johnny John, M.D.
  • Senior Vice President, Clinical Development and Medical Affairs
  • --
  • John Richard Sylvester
  • Chairman of the Board
  • 204.88K
  • Dr. Roger G. Stoll,PhD
  • Independent Director
  • 188.48K
  • Dr. Gilad Aharon, PhD
  • Independent Director
  • 172.96K
  • Elizabeth A. Czerepak
  • Independent Director
  • 188.51K
  • Steven Salamon
  • Independent Director
  • 183.96K

Trending Stocks

Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More